IRLAB Therapeutics
Develops novel treatments for Parkinson's disease and other CNS disorders.
IRLAB | ST
Overview
Corporate Details
- ISIN(s):
- SE0012675361 (+1 more)
- LEI:
- 549300JAT34LHEI0DH60
- Country:
- Sweden
- Address:
- Arvid Wallgrens backe 20, 413 46 Göteborg
- Website:
- https://irlab.se/
- Sector:
- Manufacturing
Description
IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-20 16:40 |
Valberedningen utsedd inför IRLAB:s årsstämma 2026
|
Swedish | 41.3 KB | ||
| 2025-11-20 16:40 |
Nomination committee appointed for IRLAB’s annual general meeting 2026
|
English | 40.5 KB | ||
| 2025-10-29 07:00 | Swedish | 577.5 KB | |||
| 2025-10-29 07:00 | English | 571.8 KB | |||
| 2025-10-09 17:15 |
IRLAB utser Gustaf Albèrt till ny Chief Financial Officer
|
Swedish | 39.5 KB | ||
| 2025-10-09 17:15 |
IRLAB appoints Gustaf Albèrt as the new Chief Financial Officer.
|
English | 39.5 KB | ||
| 2025-08-29 07:00 |
Ändring av antalet aktier och röster i IRLAB Therapeutics AB
|
Swedish | 47.7 KB | ||
| 2025-08-29 07:00 |
Change in number of shares and votes in IRLAB Therapeutics AB
|
English | 47.0 KB | ||
| 2025-08-27 07:00 | Swedish | 377.6 KB | |||
| 2025-08-27 07:00 | English | 373.0 KB | |||
| 2025-08-21 11:00 |
IRLAB appoints Roy Jonebrant as interim CFO
|
English | 38.2 KB | ||
| 2025-08-21 11:00 |
IRLAB utser Roy Jonebrant till tillförordnad CFO
|
Swedish | 38.8 KB | ||
| 2025-08-11 09:00 |
IRLAB's CFO Viktor Siewertz leaves the company for a new leading position
|
English | 39.6 KB | ||
| 2025-08-11 09:00 |
IRLAB:s CFO Viktor Siewertz lämnar bolaget för ny ledande position
|
Swedish | 40.0 KB | ||
| 2025-07-18 18:31 |
IRLAB announces the outcome of the company’s rights issue
|
English | 64.4 KB |
Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IRLAB Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-05 | Kristina Torfgård | Other | Buy | 9,000 | 140,850.00 SEK |
| 2024-08-05 | Kristina Torfgård | Other | Buy | 4,500 | 70,875.00 SEK |
| 2024-05-14 | Gunnar Olof Olsson | Other | Buy | 2,000 | 31,000.00 SEK |
| 2024-05-10 | Daniel Johnsson | Other | Buy | 20,000 | 259,680.00 SEK |
| 2023-04-03 | Joakim Tedroff | Other | Buy | 51,430 | 2,038,685.20 SEK |
| 2022-09-01 | Richard Godfrey | Other | Buy | 5,000 | 174,457.00 SEK |
| 2022-08-30 | Viktor Siewertz | Other | Buy | 40 | 1,420.00 SEK |
| 2022-08-29 | Viktor Siewertz | Other | Sell | 40 | 1,408.00 SEK |
| 2022-07-15 | Joakim Tedroff | Other | Other | 84,148 | N/A |
| 2022-05-31 | Viktor Siewertz | Other | Buy | 4,500 | 170,370.00 SEK |
Peer Companies
